血浆红外分子指纹用于前列腺癌检测:部分不依赖PSA信号的前瞻性证据
Lasers4Life前瞻性研究分析2024例男性血浆,包括1012例未经治疗的前列腺癌(PCa)患者、752例良性前列腺增生(BPH)患者和260例无症状对照,评估红外分子指纹(IMF)的判别性能。IMF区分PCa与无症状对照的交叉验证AUC为0.79±0.08,区分PCa与BPH的AUC为0.67±0.04;在PSA<12 ng/mL的年龄和PSA匹配亚组中,IMF的AUC为0.63,高于PSA单独检测的0.56(p<1×10⁻⁴)。结论认为IMF可检测部分不依赖PSA的PCa相关变异,但在临床相关的PCa与BPH比较中判别能力有限,需进一步多中心验证。
要点
- IMF区分PCa与无症状对照的交叉验证AUC为0.79±0.08,区分PCa与BPH的AUC为0.67±0.04。
- PSA<12 ng/mL的匹配亚组中,IMF的AUC为0.63,高于PSA的0.56(p<1×10⁻⁴)。
- 多数合并症和药物不影响IMF性能,但前列腺炎降低其判别能力。
核心结论
- 血浆IMF可在治疗前诊断场景中检测部分不依赖PSA的前列腺癌相关变异。
- IMF在临床相关的PCa与BPH比较中判别能力有限,且在全队列中未超过PSA。
- IMF作为辅助分子谱分析方法的潜力需独立多中心验证、临床显著PCa终点及在现有诊断路径中附加价值的证明。
研究设计与样本
- 前瞻性Lasers4Life研究,分析2024例男性血浆,包括1012例未经治疗PCa、752例BPH和260例无症状对照。
- 分类模型采用交叉验证评估,PCa与BPH判别另采用时间独立留出测试。
- 性能以ROC AUC量化,并按PSA分层、合并症和药物进行分析。
主要发现
- IMF区分PCa与无症状对照的交叉验证AUC为0.79±0.08,区分PCa与BPH的AUC为0.67±0.04。
- 在PSA<12 ng/mL的年龄和PSA匹配探索性亚组(200例PCa和200例BPH)中,IMF的AUC为0.63,高于PSA的0.56(p<1×10⁻⁴)。
- 多数合并症和药物未显著改变IMF性能,但前列腺炎降低判别能力。
临床怎么用
- IMF可作为辅助分子谱分析工具进一步评估,但当前证据不足以替代PSA或用于常规诊断。
- 在PSA中间浓度区间,IMF可能提供部分独立于PSA的信息,但判别能力有限。
- 临床应用前需多中心验证并证明在现有诊断路径中的附加价值。
局限性
- PCa与BPH比较中判别能力有限,全队列中未超过PSA。
- PSA<12 ng/mL亚组分析为探索性,样本量有限。
- 需独立多中心验证及临床显著PCa终点评估。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Prostate-specific antigen (PSA) testing has limited specificity, particularly at intermediate concentrations, contributing to diagnostic uncertainty in prostate cancer (PCa). Infrared molecular fingerprinting (IMF) provides a rapid plasma-based readout of systemic biochemical variation and may capture PCa-associated molecular information not fully reflected by PSA. METHODS: In the prospective Lasers4Life study, plasma from 2024 men was analysed, including 1012 treatment-naïve PCa patients, 752 men with benign prostatic hyperplasia (BPH), and 260 asymptomatic controls. Classification models were evaluated using cross-validation and, for PCa-versus-BPH discrimination, temporally independent held-out testing. Performance was quantified by receiver operating characteristic area under the curve (ROC AUC) and examined across PSA strata, comorbidities, and medications. RESULTS: IMF discriminated PCa from asymptomatic controls more strongly than from BPH, with cross-validated AUCs of 0.79 ± 0.08 and 0.67 ± 0.04, respectively. In an exploratory age- and PSA-matched subset of men with PSA below 12 ng/mL, comprising 200 PCa and 200 BPH cases, IMF showed higher discrimination than PSA alone, although performance remained modest (AUC 0.63 vs 0.56; p < 1 ×10⁻⁴). Most examined comorbidities and medications did not substantially alter IMF performance, although prostatitis reduced discrimination. CONCLUSIONS: Plasma IMF detected PCa-associated variation in a pre-treatment diagnostic setting, including information partly independent of PSA. However, discrimination was modest in the clinically relevant PCa-versus-BPH comparison and did not exceed PSA in the overall cohort. These findings support further evaluation of IMF as an adjunctive molecular-profiling approach, requiring independent multicentre validation, clinically significant PCa endpoints, and demonstration of additive value within established diagnostic pathways.
引用
- Jacob P, Chaloupka M, Eissa T, et al. Plasma infrared molecular fingerprinting for prostate cancer detection: Prospective evidence for a partially PSA-independent signal. Eur J Cancer. 2026. PMID: 42520587. doi:10.1016/j.ejca.2026.116945
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。